Gelonghui, January 25 | Zhongzhi Pharmaceutical (03737.HK) announced that the Group's net profit is expected to increase by more than 50% in the 2023 fiscal year compared to the Group's audited net profit in the same period of 2022.
The Group's anticipated increase in net profit in fiscal year 2023 is mainly due to a sharp increase in revenue from the Group's proprietary Chinese medicine sector due to the continued rise in demand for proprietary Chinese medicine products.